翟文煜
专长
一、基本情况
出诊时间：每周三中午12:00-14：00
二、教育及工作经历
2012年9月-2017年6月 吉林大学 本科
2017年7月-2020年6月 中山大学 硕士研究生
2020年9月-2023年6月 中山大学 博士研究生
2023年7月-2025年12月 中山大学肿瘤防治中心 胸科 医师 临床博士后 助理研究员
2025年12月至今 中山大学肿瘤防治中心 胸科 主治医师 助理研究员
三、主持科研项目
国家自然科学基金委员会,青年科学基金项目（C类）,外泌体LINC02178通过介导CD8+T细胞耗竭促进肺鳞癌免疫逃逸的机制研究,2025-01-01 至 2027-12-31。
四、代表性论著
1. Zhai W, Liang D, Yu X, et al. Surgery after neoadjuvant immunochemotherapy versus immuno-chemoradiotherapy in patients with cN3 non-small cell lung cancer: A cohort study in two academic centers. Lung Cancer. 2026;216:109409.
2. Zhai W, Lin Y, Zhou Y, et al. A signature of plasma exosomal miRNAs predict therapeutic efficacy to neoadjuvant immunotherapy in patients with non-small cell lung cancer. J Transl Int Med. 2025;13(6):614-617.
3. Zhai W, Zhang C, Duan F, et al. Dynamics of peripheral blood inflammatory index predict tumor pathological response and survival among patients with locally advanced non-small cell lung cancer who underwent neoadjuvant immunochemotherapy: a multi-cohort retrospective study. Front Immunol. 2024;15:1422717.
4. Zhai W, Chen S, Duan F, et al. Risk stratification and prognosis prediction based on inflammation-related gene signature in lung squamous carcinoma. Cancer Med. 2023;12(4):4968-4980.
5. Zhai WY, Duan FF, Lin YB, et al. Pan-Immune-Inflammatory Value in Patients with Non-Small-Cell Lung Cancer Undergoing Neoadjuvant Immunochemotherapy. J Inflamm Res. 2023;16:3329-3339. Published 2023 Aug 8.
6. Zhai WY, Zhao ZR, Chen S, et al. Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis. J Immunother Cancer. 2022;10(9):e005160.
7. Zhai W, Chen S, Duan F, et al. Risk stratification and prognosis prediction based on inflammation-related gene signature in lung squamous carcinoma. Cancer Med. 2023;12(4):4968-4980.
8. Zhai W, Gong L, Zheng Y, et al. Ground Glass Opacity and Adjuvant Chemotherapy in Pathological Stage IB-IIA Lung Adenocarcinoma. Front Oncol. 2022;12:851276. Published 2022 Mar 25.
9. Zhai WY, Duan FF, Wang YZ, et al. Integrative Analysis of Bioinformatics and Machine Learning Algorithms Identifies a Novel Diagnostic Model Based on Costimulatory Molecule for Predicting Immune Microenvironment Status in Lung Adenocarcinoma. Am J Pathol. 2022;192(10):1433-1447.
10. Zhai WY, Duan FF, Chen S, et al. An Aging-Related Gene Signature-Based Model for Risk Stratification and Prognosis Prediction in Lung Squamous Carcinoma. Front Cell Dev Biol. 2022;10:770550.
11. Zhai WY, Duan FF, Chen S, et al. A Novel Inflammatory-Related Gene Signature Based Model for Risk Stratification and Prognosis Prediction in Lung Adenocarcinoma. Front Genet. 2022;12:798131.
12. Zhai W, Duan F, Li D, et al. Risk stratification and adjuvant chemotherapy after radical resection based on the clinical risk scores of patients with stage IB-IIA non-small cell lung cancer. Eur J Surg Oncol. 2022;48(4):752-760.
13. Zhai WY, Duan FF, Chen S, et al. A Novel Inflammatory-Related Gene Signature Based Model for Risk Stratification and Prognosis Prediction in Lung Adenocarcinoma. Front Genet. 2022;12:798131.
14. Zhai W, Liang D, Duan F, et al. Prognostic Nomograms Based on Ground Glass Opacity and Subtype of Lung Adenocarcinoma for Patients with Pathological Stage IA Lung Adenocarcinoma. Front Cell Dev Biol. 2021;9:769881.
15. Zhai W, Zheng Y, Rong Y, et al. The impact of an N1 lymph node examination in patients with early-stage non-small cell lung cancer: a retrospective cohort study. J Thorac Dis. 2021;13(4):2184-2193.
16. Zhai W, Duan F, Zheng Y, et al. Significance of accurate hilar and intrapulmonary lymph node examination and prognostication in stage IA-IIA non-small cell lung cancer, a retrospective cohort study. World J Surg Oncol. 2020;18(1):258.
更新时间：2026.9.11
